Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigenJC Aguilar, Gerardo Guillén, Yadira Lobaina et al.|Immunology and Cell Biology|2004Cited by 87
Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigenYadira Lobaina, José Aguilar, Daniel Palenzuela et al.|Molecular Immunology|2004Cited by 46
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical TrialLeticia Rosario Cruz, Mauro Rosales, Ailyn C. Ramòn et al.|ACS Pharmacology & Translational Science|2020Cited by 45
Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategiesGerardo Guillén, Luís Herrera, Julio Aguilar et al.|Procedia in Vaccinology|2010Cited by 21
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With HeberprovacJesús A. Junco, Marta Ayala, Ranfis Rodríguez et al.|Frontiers in Oncology|2019Cited by 19